Mittal Shruti, Lee Fang Jann, Bradbury Lisa, Collett David, Reddy Srikanth, Sinha Sanjay, Sharples Edward, Ploeg Rutger J, Friend Peter J, Vaidya Anil
Oxford Transplant Centre, Oxford University Hospital NHS Trust, Oxford, UK.
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Transpl Int. 2015 Sep;28(9):1028-33. doi: 10.1111/tri.12563.
Pancreas graft failure rates remain substantial. The PDRI can be used at the time of organ offering, to predict one-year graft survival. This study aimed to validate the PDRI for a UK population. Data for 1021 pancreas transplants were retrieved from a national database for all pancreas transplants. Cases were categorized by PDRI quartile and compared for death-censored graft survival. Significant differences were observed between the UK and US cohorts. The PDRI accurately discriminated graft survival for SPK and was associated with a hazard ratio of 1.52 (P = 0.009) in this group. However, in the PTA and PAK groups, no association between PDRI quartile and graft survival was observed. This is the largest study to validate the PDRI in a European cohort and has shown for the first time that the PDRI can be used as a tool to predict graft survival in SPK transplantation, but not PTA or PAK transplantation.
胰腺移植失败率仍然很高。胰腺供体风险指数（PDRI）可在提供器官时用于预测移植器官的一年生存率。本研究旨在验证PDRI在英国人群中的有效性。从一个全国性的胰腺移植数据库中检索了1021例胰腺移植的数据。病例按PDRI四分位数分类，并比较死亡删失的移植器官生存率。观察到英国和美国队列之间存在显著差异。PDRI准确地区分了胰肾联合移植（SPK）的移植器官生存率，并且在该组中与风险比1.52相关（P = 0.009）。然而，在胰移植（PTA）和胰肾移植（PAK）组中，未观察到PDRI四分位数与移植器官生存率之间存在关联。这是在欧洲队列中验证PDRI的最大规模研究，并且首次表明PDRI可作为预测SPK移植而非PTA或PAK移植中移植器官生存率的工具。
Zotero 插件